

Progesterone and Progestins

Selected References:

- Carmichael SL, et al. 2005. Maternal progestin intake and risk of hypospadias. *Archives of Pediatrics & Adolescent Medicine*, 159(10):957-962.
- Check JH, et al. 1986. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. *Fertil Steril*, 45:575-577.
- Committee on Drugs. 2001. The transfer of drugs and other chemicals into human milk. *Pediatrics*, 108(3):776-789.
- American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. 2021. rPrediction and prevention of spontaneous preterm birth: ACOG Practice Bulletin, Number 234. *Obstet Gynecol*, 138(2):e65-e90.
- Devall AJ, et al. 2021. Progestogens for preventing miscarriage: A network meta-analysis. *Cochrane Database Sys Rev*, 4(4):CD013792.
- Duds I, et al. 2006. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. *Congenit Anom (Kyoto)*, 46:194-198.
- Fawzy M, et al. 2008. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. *Arch Gynecol Obstet*, 278(1):33-38.
- Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Littleton, Mass.: John Wright-PSG, pp 389, 391-392, 394, 443, 478, 497.
- Heinonen OP, et al. 1977. Cardiovascular birth defects and antenatal exposure to female sex hormones. *N Engl J Med*, 296:67-60.
- Massai R, et al. 2005. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. *Contraception*, 72:352-357.
- Michaelis J, et al. 1983. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. *Teratology*, 27:57-64.
- Norman JE, et al. 2009. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. *Lancet*, 373(9680):2034-2040.
- Practice Committee of the American Society for Reproductive Medicine. 2008. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. *Fertility and Sterility*, 89(4):789-792.
- Practice Committee of the American Society for Reproductive Medicine. 2012. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. *Fertility and Sterility*, 98(5):1103-1111.
- RamaRao S, et al. 2013. Progesterone vaginal ring: Introducing a contraceptive to meet the needs of breastfeeding women. *Contraception*, 88(5):591-598.
- Roy M, et al. 2020. Progesterone vaginal ring as a new contraceptive option for lactating mothers: Evidence from a multicenter non-randomized comparative clinical trial in India. *Contraception*, 102(3):159-167.
- Silver RI, et al. 1999. In vitro fertilization is associated with an increased risk of hypospadias. *J Urology*, 161(6):1954-1957.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Progesterone and Progestins

Selected References:

- Aase JM, et al. 1970. Children of mothers who took LSD in pregnancy. *Lancet* 1:100-1.
- Baquiran M, et al. 2023. Lysergic acid diethylamide toxicity. [Updated 2023 Dec 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK553216/>
- Cohen MM, et al. 1968. The effect of LSD-25 on the chromosomes of children exposed in utero. *Pediat Res* 2:486-492.
- Das, Saibal et al. Lysergic acid diethylamide: a drug of 'use'?. *Therapeutic advances in psychopharmacology* 6,3 (2016): 214-28.
- Fabro S, Sieber SM. 1968. Is lysergide a teratogen? *Lancet* 1(7543):639.
- Fuentes, Juan & Fonseca, Francina & Elices, Matilde & Farré, Magí & Torrens, Marta. (2020). Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. *Frontiers in Psychiatry*. 10. 943. 10.3389/fpsy.2019.00943.
- Jacobson CB, Berlin CM. 1972. Possible reproductive detriment in LSD users. *JAMA* 222(11):1367-1373.
- Haden, M, & Woods, B. 2020. LSD overdoses: three case reports. *Journal of Studies on Alcohol and Drugs*, 81(1), 115-118.
- Long SY. 1972. Does LSD induce chromosomal damage and malformations? A review of the literature. *Teratology* 6(1):75-90.
- McElhatton PR. 2000. Fetal effects of substances of abuse. *J Toxicol Clin Toxicol*; 38:194-5.
- McGlothlin WH, et al. 1970. Effect of LSD on human pregnancy. *JAMA*. 1; 212(9):1483-7.
- Mueller, B. A., Daling, J. R., Weiss, N. S., & Moore, D. E. (1990). Recreational drug use and the risk of primary infertility. *Epidemiology (Cambridge, Mass.)*, 1(3), 195-200
- Papac DI and Foltz RL. 1990. Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. *J Anal Toxicol*. 14(3):189-90.
- Robinson JT, et al. 1974. Chromosome aberrations and LSD. A controlled study in 50 psychiatric patients. *J Psychiatry*. 125(0):238-44

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Progesterone and Progestins

Selected References

- Bristol-Myers Squibb. 2019. Available at <https://clinicaltrials.gov/ct2/show/record/NCT01087125?view=record>
- Deroncourt A, et al. 2023. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: Insights from an analysis of the World Health Organization pharmacovigilance database (VigiBase®). *BioDrugs*, 37(1):73-87.
- E.R. Squibb and Sons, L.L.C. (Last updated: October 30, 2023). Orenzia drug label. Source: National Library of Medicine. Available at <https://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?setid=0836c6ac-ee37-5640-2fed-a3185a0b16eb>.
- Ghalandari N, et al. 2022. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance. *Br J Clin Pharmacol*, 88(12):5378-5388.
- Kumar M, et al. 2015. Pregnancy outcomes following exposure to abatacept during pregnancy. *Semin Arthritis Rheum*, 45(3):351-356.
- Makol A, et al. 2011. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. *Drugs*, 71(15):1973-1987.
- National Institutes of Health. (Last updated February 24, 2024). COVID-19 Treatment Guidelines: Abatacept. Available at <https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/abatacept/> through August 16, 2024.
- Ojeda-Urbe M, et al. 2013. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. *Clin Rheumatol*, 32(5):695-700.
- Ostensen M and Förger F. 2011. Treatment with biologics of pregnant patients with rheumatic diseases. *Curr Opin Rheumatol*, 23(3):293-298.
- Partlett R and Roussou E. 2011. The treatment of rheumatoid arthritis during pregnancy. *Rheumatol Int*, 31(4):445-449.
- Pham T., et al. 2012. Abatacept therapy and safety management. *Joint Bone Spine*, 79 Suppl 1:3-84.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Progesterone and Progestins

Selected References:

- Ali, R, et al. 2022. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. *BMC gastroenterology*; 22.1: 1-10.
- Anderka M, et al. 2012. National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol*; 94:22-30.
- Andersen ABT, et al. 2012. Prenatal exposure to acid-suppressive drugs and the risk of toddler asthma: a population-based Danish cohort study. *Alim Pharmacol Ther*; 35:1190-1198.
- Anderson P. 2018. Treating gastroesophageal reflux and heartburn while breastfeeding. *Breastfeed Med*;13(7):463-4.
- Bank, T, et al. 2024. Challenges in Conducting Clinical Trials for Preeclampsia. *Curr Hypertens Rep* 26, 59-68.
- Bor S, et al. 2017. The levels of pantoprazole in human breast milk and plasma: two compartment model. *Neurogastroenterol Motil*; 29:79-80.
- Dehlink E, et al. 2009. First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. *Clin Exp Allergy* 39:246-53.
- Diav-Citrin O, et al. 2005. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. *Aliment Pharmacol Ther*; 21:269-75.
- Erichsen R, et al. 2014. Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring. *Am J Ther*; 21: 254-259.
- Gill SK et al. 2009. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. *Am J Gastroenterol*; 104(6): 1541-1545.
- Hastie R, et al. 2019. Proton pump inhibitors and preeclampsia risk among 157 720 women: a Swedish population register-based cohort study. *Hypertension*; 73(5):1097-103.
- Huijgen NA. 2016. Are proton-pump inhibitors harmful for the semen quality of men in couples who are planning pregnancy? *Fertility and Sterility*, 106(7), 1666-1672.
- Kallen B. 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. *Br J Obstet Gynaecol*; 105:877-881.
- Kallen B. 2001. Use of omeprazole during pregnancy—no hazard demonstrated in 955 infants exposed during pregnancy. *Eur J Obstet Gynecol Reprod Biol*; 96:63-68.
- Keihani, S. et al. 2018. Proton-pump inhibitor use does not affect semen quality in subfertile men. *Asian journal of andrology*, 20(3), 290.
- Lalkin A, et al. 1998. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. *Am J Obstet Gynecol*; 179(3 Pt 1): 727-730.
- Li, C, et al. 2020. Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy. *Alimentary pharmacology & therapeutics*; 51.4: 410-420.

- Mahadevan, Uma. 2007. "Gastrointestinal Medications in Pregnancy." *Best Practice & Research Clinical Gastroenterology* 21(5): 849-77.
- Majithia, R., & Johnson, D. A. (2012). Are Proton Pump Inhibitors Safe during Pregnancy and Lactation? 10.
- Marshall JK, et al. 1998. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. *Can J Gastroenterol*; 12: 225-227.
- Matok I, et al. 2012. The safety of fetal exposure to proton-pump inhibitors during pregnancy. *Dig Dis Sci*; 57:699-705.
- Mumtaz, N, et al. Harmful Consequences of Proton Pump Inhibitors on Male Fertility: An Evidence from Subchronic Toxicity Study of Esomeprazole and Lansoprazole in Wistar Rats. *International Journal of Endocrinology*.
- Nikfar S, et al. 2002. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. *Dig Dis Sci*; 47:1526-9.
- Neuman R, et al. 2022. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1). *Hypertension*, vol. 79,6: 1297-1307.
- Pasternak B, Hviid A. 2010. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. *N Engl J Med*; 363:2114-2123.
- Saito J, et al. 2020. Esomeprazole During Pregnancy and Lactation: Esomeprazole Levels in Maternal Serum, Cord Blood, Breast Milk, and the Infant's Serum. *Breastfeeding Medicine*, bfm.2020.0175.
- Thélin CS, & Richter JE. 2020. Review article: the management of heartburn during pregnancy and lactation. *Alimentary Pharmacology & Therapeutics*, 51(4), 421-434.
- Yitshak-Sade M, et al. 2016. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. *J Clinic Pharmacol*; 56: 116-123

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Progesterone and Progestins

Selected References:

- Affendi Raja RA, et al. 2022. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. *BMC Gastroenterology*, 22:219-229.
- Courtney TP, et al. 1988. Excretion of famotidine in breast milk. *Br J Clin Pharmacol*, 626:639P.
- Garbis H, et al. 2005. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. *Reprod Toxicol*, 19:453-458.
- Hagemann, TM, 1998. Gastrointestinal medications and breastfeeding. *Journal of Human Lactation*, 14(3):259-262.
- Kallen B, 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. *Journal of Obstetrics and Gynecology*, 105:877-881.
- Magee LA, et al. 1996. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. *Dig Dis Sci*, 41(6):1145-1149.
- Matok I, et al. 2010. The safety of H (2)-blockers use during pregnancy. *J Clin Pharmacol*, 50(1):81-87.
- Orenstein SR, Shalaby TM, Devandry SN, et al. 2003. Famotidine for infant gastro-oesophageal reflux: A multi-centre, randomized, placebo-controlled, withdrawal trial. *Aliment Pharmacol Ther*, 7(9):1097-107.
- Savarino V, et al. 1988. Famotidine has no significant effect on gonadal function in man. *Gastroenterol Clin Biol*, 12:19-22.
- Wang X, et al. 2011. Pharmacokinetics of famotidine in pregnant women. *Am J Obstet Gynecol.*, 204: 72-73.
- Yitshak-Sade M, et al. 2016. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. *J Clin Pharmacol*, 56(1):116-123.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.